Properties (39)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Otsuka_Pharmaceutical_in_2010
|
| gptkbp:awards |
Industry awards for innovation
|
| gptkbp:CEO |
gptkb:James_S._Manuso
|
| gptkbp:clinicalTrials |
Targeted therapies
Multiple ongoing clinical trials Focus on innovative clinical trials Phase I, II, and III clinical trials |
| gptkbp:collaborations |
Collaboration with academic institutions
Partnership with pharmaceutical companies Partnership_with_the_National_Cancer_Institute |
| gptkbp:community_engagement |
Engagement in community health initiatives
|
| gptkbp:employees |
Approximately 200
|
| gptkbp:focus |
Cancer therapeutics
|
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Harold_B._Smith
|
| gptkbp:headquarters |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astex Pharmaceuticals
|
| gptkbp:investmentFocus |
Significant investment in R&D
Publicly_traded_on_NASDAQ |
| gptkbp:leadership |
Experienced leadership team
|
| gptkbp:market |
Global market presence
|
| gptkbp:mission |
To improve patient outcomes through innovative therapies.
|
| gptkbp:notableEvent |
gptkb:Dacogen
Zykadia |
| gptkbp:partnerships |
Collaboration_with_AstraZeneca
|
| gptkbp:patentCitation |
Numerous patents in drug development
|
| gptkbp:publications |
Numerous scientific publications
|
| gptkbp:regulatoryCompliance |
FDA_approved_drugs
|
| gptkbp:research_areas |
Oncology
Drug discovery Hematology |
| gptkbp:subsidiary |
gptkb:Astex_Pharmaceuticals,_Inc.
|
| gptkbp:technology |
High-throughput screening
Structure-based drug design Fragment-based drug design |
| gptkbp:tributaryOf |
Diverse pipeline of drug candidates
|
| gptkbp:type |
Public company
|
| gptkbp:website |
www.astx.com
|